Real-world data analysis compares GLP-1 receptor agonists and SGLT-2 inhibitors for liver outcomes in MASH patients, examining cirrhosis, liver cancer, and enzyme changes.
Liver outcomes comparedCirrhosis, HCC, and enzyme changes evaluated between GLP-1 RA and SGLT-2 inhibitor users in MASH
What the researchers found
Real-world comparison of GLP-1 RAs versus SGLT-2 inhibitors in MASH patients evaluated cirrhosis incidence, hepatocellular carcinoma rates, and liver enzyme profile changes.
Why it matters
MASH affects millions and has limited treatment options. Knowing which common diabetes drug better protects the liver could change prescribing practices immediately.
How the study worked
Retrospective cohort study using de-identified electronic health records from the TriNetX network, comparing MASH patients on GLP-1 RAs versus SGLT-2 inhibitors.
What this study cannot tell us
Retrospective observational design — cannot prove causation. EHR data may have coding inconsistencies. Confounding by indication likely (patients may receive different drugs for different reasons).
How to read the evidence
Large retrospective real-world study — provides practical comparative data but limited by observational design and confounding.
When this study was published
Published in 2026; uses current real-world prescribing data.
The bigger picture
As metabolic liver disease becomes a leading cause of liver transplantation, repurposing diabetes drugs for liver protection represents a practical, near-term therapeutic strategy.
Questions still open
- Should MASH patients preferentially receive GLP-1 drugs over SGLT-2 inhibitors?
- Do the liver benefits extend to patients without diabetes?
Common questions
Which diabetes drug is better for fatty liver disease?
What is MASH?
Read the original research
Liver gains beyond glycemic control: GLP-1 vs. SGLT2 in metabolic dysfunction-associated steatohepatitis (MASH): A real-world data analysis.
Clinics and research in hepatology and gastroenterology, 50(2), 102760
Citation
Beyene, Elizabeth; Chirumamilla, Lakshmi; Bisrat, Mekdem; Bowen, Allan; Fetle, Yonas; Wilkerson, Brandon; Wudeneh, Addishiwot; Gillani, Syed Fahad; Larbi, Daniel; Michael, Miriam. (2026). Liver gains beyond glycemic control: GLP-1 vs. SGLT2 in metabolic dysfunction-associated steatohepatitis (MASH): A real-world data analysis.. Clinics and research in hepatology and gastroenterology, 50(2), 102760. https://doi.org/10.1016/j.clinre.2026.102760